Markets
← Back to Stocks
LLY
ELI LILLY + CO
Health Care · Pharmaceuticals
$916.83
-0.13%
Vol: 0.0M
Araverus Market Read
Thursday, March 19, 2026
HSBC downgrade and obesity market concerns weigh significantly on pre-market decline as competition intensifies
Eli Lilly declined $10.57 (-1.05%) in pre-market to $993 and fell $0.24 (-0.03%) after-hours to $930.59, reversing from Tuesday's close at $1,003.57. HSBC downgraded the stock citing smaller-than-expected obesity market and increased competition, cutting price target to $850 from $1,070, causing 5.9% single-day decline. Investor concerns about Zepbound and Mounjaro market saturation and competitive threats from other GLP-1 manufacturers create near-term headwinds despite blockbuster drug potential.
Price 50d 200d
Previous Market Reads
2 of 2 days↑
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$821.2B
P/E (TTM)40.0
Forward P/E21.8
Beta0.43
Div Yield68.00%
Prev Close$918.05
RSI (14-Day)
18Oversold
0305070100
52-Week Range
$623.78$916.83$1,133.95
From High-19.1%
From Low+47.0%
Moving Averages
50d SMA
$1,027.85-10.8%
200d SMA
$889.41+3.1%
Price between 50d and 200d. Testing 50d support.
Returns
1W
-6.2%
1M
-10.2%
3M
-12.9%
6M
+21.0%
1Y
+12.3%
YTD
-15.0%
Volume
Today30K
20d Avg2.9M
Ratio0.01x